Atrophic Acne Scars Atrophic Acne Scars
Conditions
Interventions
Participants were treated with 3 sessions of 755 nm Picosecond Laser with Diffractive Lens Array with 1 month interval.
Then participants were appointed for follow-up at 1 , 3 , 6 after completing 3
Experimental Device
755 nm Picosecond Laser with Diffractive Lens Array
Sponsors
Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand
Eligibility
Sex/Gender
All
Age
20 Years to 50 Years
Inclusion criteria
Inclusion criteria: 1. Participants aged 20 to 50 years 2. Participants with atrophic acne scars on the face 3. Participants who willingly consent to participate in the study 4. Participants with moderate to severe acne scar according to the Global Acne Scar Grading System assessed by dermatologist
Exclusion criteria
Exclusion criteria: 1. Participants who are pregnant or breastfeeding, as determined through medical history taking by the investigator 2. Participants with a history of collagen-related disorders such as Cushing syndrome or Ehlers-Danlos syndrome 3. Participants with facial dermatitis, wounds, or active skin infections 4. Participants with cancer, currently undergoing cancer treatment, or with a history of skin cancer in the treatment area 5. Participants with a history of immunodeficiency, including those infected with HIV or diagnosed with AIDS, as determined through medical history taking by the investigator 6. Participants with a history of allergy to local anesthetics 7. Participants with a history of abnormal photosensitivity 8. Participants who have received facial treatment with dermal fillers, botulinum toxin, collagen biostimulators, platelet-rich plasma (PRP), or thread lifting within 6 months prior to study enrollment 9. Participants who have received laser treatment for acne scars on the face within 6 months prior to study enrollment 10. Participants with a history of keloids or other abnormal scarring in the treatment area 11. Participants who have received isotretinoin treatment within 6 months prior to study enrollment 12. Participants who have received retinoids or vitamin A derivatives within 3 months prior to study enrollment 13. Participants with a history of psychiatric disorders, as determined through medical history taking by the investigator 14. Participants with any condition deemed by the investigator to pose a potential safety risk if enrolled in the study 15. Participants who do not consent to photographic documentation for treatment outcome assessment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Texture Baseline, 1 month after 1st treatment, 1 month after 2nd treatment, 1 month after 3rd treatment, 3 months after 3rd treatment, 6 months after 3rd treatment Antera 3D,volume depression Baseline, 1 month after 1st treatment, 1 month after 2nd treatment, 1 month after 3rd treatment, 3 months after 3rd treatment, 6 months after 3rd treatment Antera3 D | — |
Secondary
| Measure | Time frame |
|---|---|
| Pigmentation Baseline, 1 month after 1st treatment, 1 month after 2nd treatment, 1 month after 3rd treatment, 3 months after 3rd treatment, 6 months after 3rd treatment Antera3D,Redness Baseline, 1 month after 1st treatment, 1 month after 2nd treatment, 1 month after 3rd treatment, 3 months after 3rd treatment, 6 months after 3rd treatment Antera 3D,Physician improvement scale 1 month after 1st treatment, 1 month after 2nd treatment, 1 month after 3rd treatment, 3 months after 3rd treatment, 6 months after 3rd treatment percent improvement,Patient improvement scale 1 month after 1st treatment, 1 month after 2nd treatment, 1 month after 3rd treatment, 3 months after 3rd treatment, 6 months after 3rd treatment percent improvement,Safety Baseline, 1 month after 1st treatment, 1 month after 2nd treatment, 1 month after 3rd treatment, 3 months after 3rd treatment, 6 months after 3rd treatment Adverse event | — |
Countries
Thailand
Contacts
Public ContactWoraphong Manuskiatti
Department of Dermatology, Faculty of medicine Siriraj hospital, Mahidol university
Outcome results
None listed